Expensive cutting-edge medicine – Could the drug Zolgensma cause cancer?
The US Food and Drug Administration (FDA) is investigating reports of cancer cases among children treated with Zolgensma, a gene therapy developed by Novartis for spinal muscular atrophy (SMA). While over 6,000 patients have received the treatment since approval, nine tumor reports have been filed, with some analyses detecting viral DNA from the therapy’s vector within the tumor tissue. Experts note that while animal studies have long indicated potential carcinogenic risks associated with such adeno-associated virus vectors, current data is insufficient to establish a reliable risk rate due to varying follow-up times and incomplete molecular analysis. Zolgensma has gained significant public attention partly because it is the world’s most expensive medication covered by insurance, costing approximately 2.1 million Swiss francs per dose.
The United States Food and Drug Administration is currently investigating reports of cancer diagnoses in several children who underwent treatment with Zolgensma. The Swiss pharmaceutical company Novartis confirmed receiving nine reports of tumors in pediatric patients globally since the gene therapy received initial authorization in 2019. This scrutiny follows the emergence of potential safety concerns surrounding the medication, which was originally celebrated as a major medical breakthrough for treating spinal muscular atrophy. Spinal muscular atrophy is a rare hereditary condition characterized by the death of nerve cells, leading to progressive muscle weakness. Without intervention, the disease often results in death before a child reaches their second birthday. Zolgensma addresses the root genetic cause of the illness by replacing the function of the missing or non-functioning SMN1 gene. The therapy involves a one-time intravenous infusion using modified viruses, known as adeno-associated virus vectors, which act as carriers to insert a healthy copy of the gene into body cells. Novartis stated in a press release that more than 6,000 patients worldwide have received the treatment through clinical trials, special access programs, and routine care. Among the nine reported tumor cases, analyses of tumor tissue in two instances revealed the presence of DNA from the viral vector used in the therapy. Both children in these specific cases have undergone treatment and remain under medical observation. The FDA indicated that the tumors affected the central and peripheral nervous systems, the spine area, and the kidney. Toni Cathomen, director of the Institute for Transfusion Medicine and Gene Therapy at the University Hospital Freiburg in Germany, noted that animal studies have long demonstrated that such gene therapies can induce cancer. He observed that findings now exist for four children involving cancer after experimental treatments, including two cases linked to Zolgensma. However, Cathomen emphasized that the long-term cancer risk cannot yet be reliably quantified. He argued that nine tumor reports among over 6,000 treated individuals do not yield a dependable risk rate, noting that not all tumors are necessarily therapy-induced, follow-up periods vary, and molecular analysis remains incomplete. The British patient organization SMA UK reported that detailed examinations have so far covered the tumors of three of the nine affected children. Vector DNA integration was found in two of these cases, while no link between the treatment and the tumor appeared in the third case. Limited information is available regarding the affected children at this stage, with further details pending from regulatory bodies. Novartis highlighted that the potential risk of tumor formation resulting from vector DNA integration into the genome is already documented in the product information for Zolgensma. The drug gained global attention upon its launch in 2019 due to its unprecedented cost. Priced at approximately 2.1 million dollars per dose, it was considered the most expensive medicine in the world at the time. Prices varied by country and region, with costs reaching around 2.1 million Swiss francs per dose in some markets. The high price point led to public debate, including a lottery organized by Novartis in February 2020 to fund treatment for 100 children. Novartis continues to review new safety information and all reported cases. The company maintains that the therapy targets the fundamental cause of the disease by delivering a functional gene copy to cells in children under the age of two. Regulatory agencies are monitoring the situation as they evaluate the connection between the gene therapy and the observed malignancies. The investigation aims to determine whether the viral vectors play a role in the development of these cancers in the treated population.
Novartis has disclosed nine global cases of tumors in children who were previously treated with Zolgensma, a gene therapy for spinal muscular atrophy authorized in 2019. The company stated that in two instances, genetic material from the viral vector used in the therapy was detected within the patients' DNA, suggesting a potential causal link. These two children have undergone treatment and remain under medical observation, while further investigations are ongoing for the remaining cases. Since its launch, over 6,000 patients worldwide have received the therapy, which was initially noted for being the world's most expensive drug at approximately $2.1 million per dose. Regulatory authorities and patient organizations are currently awaiting additional data to fully assess the safety profile of the medication.
Bias read (Center): The article relies exclusively on corporate disclosures and objective medical data without employing loaded language or omitting critical context regarding the safety concerns.
Why factuality (95): Highly accurate and concise. It sticks strictly to the verified facts: 9 cases, 2 with genetic material detection, and the context of the 2019 approval. It avoids unverified specifics found in Article 0, aligning perfectly with the available evidence.
Why objectivity (90): Very neutral and professional tone. Uses standard journalistic phrasing ('hailed as a medical breakthrough', 'coming under scrutiny') without injecting personal opinion or emotional language. Presents the situation as a matter of regulatory scrutiny rather than a definitive disaster or success story
The US Food and Drug Administration (FDA) is investigating reports of cancer cases among children treated with Zolgensma, a gene therapy developed by Novartis for spinal muscular atrophy (SMA). While over 6,000 patients have received the treatment since approval, nine tumor reports have been filed, with some analyses detecting viral DNA from the therapy’s vector within the tumor tissue. Experts note that while animal studies have long indicated potential carcinogenic risks associated with such adeno-associated virus vectors, current data is insufficient to establish a reliable risk rate due to varying follow-up times and incomplete molecular analysis. Zolgensma has gained significant public attention partly because it is the world’s most expensive medication covered by insurance, costing approximately 2.1 million Swiss francs per dose.
Bias read (Center): The article maintains a neutral tone by presenting FDA investigations, expert opinions on statistical limitations, and factual costs without using loaded language or taking a stance on regulatory policy.
Why factuality (85): Accurately reflects the core facts of the event (FDA review, 9 tumor reports, 2 linked cases) based on the cross-source consensus. However, it includes specific details like 'over 6000 patients' and specific tumor locations (spine, kidney) that are not present in the provided reference text, making
Why objectivity (70): The headline uses a question mark but implies causality, which is slightly leading compared to the neutral reporting in the body. The inclusion of a photo caption describing a specific child adds a human element that borders on emotional appeal, though the main text remains relatively factual.
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.